GLP1R and metabolic dysfunction-associated steatotic liver disease: Concerning the newer antihyperglycemic agents, only glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors seem to be useful in patients with NAFLD or NASH.